Answer
In biochemical in vitro studies, avapritinib inhibits PDGFRA D842V and KIT D816V (IC50 0.24 and 0.27 nM, respectively), mutants associated with imatinib, sunitinib and regorafenib resistance, and is more potent against clinically relevant KIT exon 11 and exon 17 mutants than wild-type KIT.
Sources for this answer
- AYVAKYT 300 mg film-coated tabletsBlueprint Medicines (Netherlands) B.V. · emc · SmPC §5.1 Pharmacodynamic properties · Version 3Document updated
Sources checked